Markus J V VÃ¤hÃ¤-Koskela

List of Publications by Year
in descending order

52 papers	2,172 citations	186265 28 h-index	233421 45 g-index
55 all docs	55 docs citations	55 times ranked	2756 citing authors

#	Article	IF	Citations
1	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. Briefings in Bioinformatics, 2022, 23, .	6.5	7
2	Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring. Cancers, 2022, 14, 525.	3.7	7
3	Exploration of databases and methods supporting drug repurposing: a comprehensive survey. Briefings in Bioinformatics, 2021, 22, 1656-1678.	6.5	66
4	Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opinion on Drug Discovery, 2021, 16, 977-989.	5.0	68
5	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	10.3	28
6	Immunogenomic Landscape of Hematological Malignancies. Cancer Cell, 2020, 38, 380-399.e13.	16.8	109
7	Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia, 2020, 34, 3186-3196.	7.2	22
8	Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell Chemical Biology, 2018, 25, 224-229.e2.	5.2	124
9	Interactive visual analysis of drugâ€“target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing. Briefings in Bioinformatics, 2018, , .	6.5	25
10	Drug Target Commons 2.0: a community platform for systematic analysis of drugâ€“target interaction profiles. Database: the Journal of Biological Databases and Curation, 2018, 2018, 1-13.	3.0	36
11	PROX1 is a transcriptional regulator of MMP14. Scientific Reports, 2018, 8, 9531.	3.3	26
12	Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. Current Cancer Drug Targets, 2018, 18, 124-138.	1.6	13
13	Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity. Blood, 2018, 132, 2210-2210.	1.4	2
14	Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations. Blood, 2018, 132, 2743-2743.	1.4	0
15	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunology Research, 2017, 5, 157-169.	3.4	36
16	Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas. Translational Oncology, 2017, 10, 772-779.	3.7	5
17	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses, 2017, 9, 271.	3.3	39
18	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFÎ± Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Journal of Immunotherapy, 2016, 39, 343-354.	2.4	21

#	Article	IF	Citations
19	Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Molecular Therapy - Oncolytics, 2016, 3, 16002.	4.4	32
20	Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting. OncoImmunology, 2016, 5, e1136046.	4.6	17
21	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2016, 24, 175-183.	8.2	26
22	Adenoviral Delivery of Tumor Necrosis Factor-Î± and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Molecular Therapy, 2016, 24, 1435-1443.	8.2	37
23	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GMâ€CSF: <scp>R</scp>esults <i>in vitro</i>, in rodents and in humans. International Journal of Cancer, 2015, 137, 1775-1783.	5.1	41
24	Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells. PLoS ONE, 2015, 10, e0120496.	2.5	4
25	Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunology Research, 2015, 3, 915-925.	3.4	61
26	Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles. BMC Veterinary Research, 2015, 11, 170.	1.9	17
27	MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Journal of Virology, 2015, 89, 10637-10647.	3.4	30
28	GMCSFâ€armed vaccinia virus induces an antitumor immune response. International Journal of Cancer, 2015, 136, 1065-1072.	5.1	23
29	Oncolytic adenovirus and doxorubicinâ€based chemotherapy results in synergistic antitumor activity against softâ€tissue sarcoma. International Journal of Cancer, 2015, 136, 945-954.	5.1	51
30	Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors. PLoS ONE, 2015, 10, e0131242.	2.5	38
31	Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. Molecular Therapy - Oncolytics, 2014, 1, 14006.	4.4	8
32	Tumor Restrictions to Oncolytic Virus. Biomedicines, 2014, 2, 163-194.	3.2	52
33	Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles. Molecular Therapy - Oncolytics, 2014, 1, 14002.	4.4	11
34	Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma. Journal of Virology, 2013, 87, 2363-2366.	3.4	19
35	Model-based rational design of an oncolytic virus with improved therapeutic potential. Nature Communications, 2013, 4, 1974.	12.8	38
36	MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver. PLoS ONE, 2013, 8, e54506.	2.5	24

#	Article	IF	Citations
37	Oncolytic adenoviruses. OncoImmunology, 2012, 1, 979-981.	4.6	31
38	Oncolytic Adenoviruses for Cancer Immunotherapy. Advances in Cancer Research, 2012, 115, 265-318.	5.0	61
39	Interferon-Î² Sensitivity of Tumor Cells Correlates With Poor Response to VA7 Virotherapy in Mouse Glioma Models. Molecular Therapy, 2012, 20, 1529-1539.	8.2	16
40	Propagation, Purification, and In Vivo Testing of Oncolytic Vesicular Stomatitis Virus Strains. Methods in Molecular Biology, 2012, 797, 127-140.	0.9	35
41	Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. Molecular Therapy, 2010, 18, 896-902.	8.2	27
42	A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Molecular Therapy, 2010, 18, 1123-1129.	8.2	85
43	Novel oncolytic viruses: Riding high on the next wave?. Cytokine and Growth Factor Reviews, 2010, 21, 177-183.	7.2	28
44	Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice. PLoS ONE, 2010, 5, e8603.	2.5	51
45	Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. International Journal of Cancer, 2008, 123, 1704-1711.	5.1	40
46	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14981-14986.	7.1	161
47	Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice. Biochemical and Biophysical Research Communications, 2007, 355, 776-781.	2.1	9
48	Oncolytic viruses in cancer therapy. Cancer Letters, 2007, 254, 178-216.	7.2	281
49	Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. International Journal of Cancer, 2007, 121, 863-870.	5.1	29
50	Oncolytic Capacity of Attenuated Replicative Semliki Forest Virus in Human Melanoma Xenografts in Severe Combined Immunodeficient Mice. Cancer Research, 2006, 66, 7185-7194.	0.9	55
51	A Novel Neurotropic Expression Vector Based on the Avirulent A7(74) Strain of Semliki Forest Virus. Journal of NeuroVirology, 2003, 9, 1-15.	2.1	47
52	Semliki Forest Virus A7(74) Transduces Hippocampal Neurons and Glial Cells in a Temperature-Dependent Dual Manner. Journal of NeuroVirology, 2003, 9, 16-28.	2.1	49